Immunome, Inc. (NASDAQ:IMNM) CEO Buys $630,183.78 in Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall acquired 66,057 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares in the company, valued at $4,633,511.22. This represents a 15.74 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Immunome Stock Performance

NASDAQ IMNM opened at $11.53 on Wednesday. The business’s fifty day moving average is $12.49 and its 200 day moving average is $13.55. Immunome, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $30.96. The company has a market capitalization of $719.70 million, a PE ratio of -1.42 and a beta of 1.82.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of research reports. Piper Sandler decreased their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Stephens initiated coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $28.83.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Sei Investments Co. bought a new position in shares of Immunome during the 1st quarter valued at approximately $469,000. Vanguard Group Inc. boosted its position in shares of Immunome by 16.1% in the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after purchasing an additional 279,712 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Immunome by 113.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after purchasing an additional 1,194,451 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Immunome by 10.6% during the 1st quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock valued at $37,957,000 after purchasing an additional 146,943 shares during the period. Finally, California State Teachers Retirement System purchased a new position in shares of Immunome during the 1st quarter valued at $807,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.